Table 1. Overview of 17 included patients with high-risk MDS or MDS with high risk features.
| AZA no. | Age at diagnosis | Sex | Diagnosis | Cycles received |
|---|---|---|---|---|
| AZA 1 | 79 | f | MDS | 14 |
| AZA 2 | 63 | m | MDS | 9 |
| AZA 4 | 73 | m | AML | 6 |
| AZA 5 | 78 | f | CMML | 41 |
| AZA 7 | 39 | m | MDS | 9 |
| AZA 8 | 64 | m | MDS | 12 |
| AZA 10 | 84 | m | CMML | 16 |
| AZA 12 | 78 | m | AML | 3 |
| AZA 14 | 77 | f | MDS | 12 |
| AZA 16 | 76 | m | MDS | 4 |
| AZA 17 | 70 | f | AML | 3 |
| AZA 19 | 67 | f | AML | 10 |
| AZA 20 | 75 | f | MDS | 9 |
| AZA 22 | 62 | m | MDS | 10 |
| AZA 24 | 73 | f | MDS | 4 |
| AZA 27 | 76 | m | MDS | 26 |
| AZA 28 | 74 | m | MDS/AML | 12 |
Abbreviations: AML, acute myeloid leukemia; CMML, chronic myelomonocytic leukemia; f, female; m, male; MDS, myelodysplastic syndrome.